KRAS protein is a key driver of most cases of pancreatic cancer. KRAS, working via leukemia inhibitory factor, promotes the generation and maintenance of pancreatic cancer stem cells. LIF shows promise as a target for pancreatic cancer treatment. LAKE TAHOE, Nev. — Pancreatic cancer is one of the...
Tue, Jun 19 2012
Filed under: Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, stem cells, pancreatic cancer, KRAS, Pancreatic Cancer: Progress and Challenges, leukemia inhibitory factor, Dr. Man-Tzu Wang, LIF